Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects
 with focal epilepsy.
Inclusion Criteria:

 -  Males/Females from 18 to 65 years of age (minimum body weight of 40 kg)

 -  Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures
 whether or not secondarily generalized.

 -  Subjects who have been treated for epilepsy for ≥6 months and are currently
 uncontrolled while being treated with 1-3 concomitant AED(s).

 -  Female subjects without childbearing potential; Female subjects with childbearing
 potential are eligible if they use a medically accepted non-hormonal contraceptive
 method

 Exclusion Criteria:

 -  Seizures occurring in clusters. Status epilepticus within 6 months of Visit 1. History
 of non-epileptic seizures

 -  Subjects on vigabatrin

 -  Subjects on felbamate, unless treatment has been continuous for >2 years

 -  Ongoing psychiatric disease other than mild controlled disorders.

 -  Subjects with clinically significant organ dysfunction

 -  Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients

 -  Pregnant or lactating women.

 -  Subjects currently taking levetiracetam (LEV).

 -  Use of benzodiazepines (for any indication) taken at a higher frequency than an
 average of once a week, unless counted as one of the concomitant AEDs.